Influence of CYP2B6 and ABCB1 SNPs on Nevirapine Plasma Concentrations in Burundese HIV-positive Patients Using Dried Sample Spot Devices

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2012 Jun 12

PMID 22680342

Citations 14

Authors

Andrea Calcagno

Antonio DAvolio

Marco Simiele

Jessica Cusato

Roberto Rostagno

Valentina Libanore

Lorena Baietto

Marco Siccardi

Stefano Bonora

Giovanni Di Perri

Affiliations

Soon will be listed here.

Abstract

What Is Already Known About This Subject: • Nevirapine pharmacokinetics are affected by several factors including CYP2B6 single nucleotide polymorphisms (SNPs). These genetic profiles are more common in African patients and they affect the drug clearance being associated with higher trough concentrations. Pharmacokinetic/pharmacogenetic (PK/PG) studies are difficult to perform in remote areas where refrigeration is not available, although dried plasma and dried blood methods have been validated.

What This Study Adds: • Dried plasma spots are useful tools for studying nevirapine PK with a good association to plasma concentrations and they can be used in rural areas since a cold chain is not necessary. Dried blood spots can be used to store and analyze patients' DNA for PG polymorphisms. Nevirapine trough concentrations in Burundese patients, not studied so far, are above the target concentration (3000 ng ml(-1) ) in 84% of patients. CYP2B6 (both at position 516 and 983) but not ABCB1 (3435 and 1236) SNPs as well as age correlate with higher nevirapine exposure.

Aims: The pharmacokinetics (PK) and pharmacogenetics (PG) of nevirapine have been studied in rich and limited-resource countries. CYP2B6 single nucleotide polymorphisms (SNPs) have been associated with decreased drug clearance. We evaluated the PG determinants of nevirapine trough concentrations in a rural cohort in Burundi using easy to store and transport dried sample spot devices.

Methods: A cross-sectional analysis in HIV-positive nevirapine-treated patients in Kiremba, north of Burundi, was performed in 2009. After blood withdrawal whole blood was stored on dried blood spots and plasma (after centrifugation) was placed on dried plasma spot devices and stored at room temperature. Nevirapine plasma and dried sample spot concentrations were compared to test the clinical usefulness of this method. SNPs in CYP2B6 and ABCB1 (using a real time PCR technique) were analyzed and associated with nevirapine plasma trough concentrations.

Results: Nevirapine concentrations measured on dried plasma spot devices were highly related to plasma concentrations in 60 patients, although a negative bias was observed (-18%). Nevirapine trough concentrations were above the target concentration (3000 ng ml(-1) ) in 84% of patients and they were associated with CYP2B6 SNPs (both at position 516 and 983). No effect of ABCB1 SNPs was noted.

Conclusions: Dried plasma spot devices are accurate tools for measuring nevirapine concentrations in rural settings where refrigeration is not available, despite a moderate underestimation bias. They allowed the evaluation of nevirapine concentrations in a cohort of HIV-infected people in rural Burundi, confirming very good exposure and correlation with PG polymorphisms in the CYP2B6 encoding gene.

Citing Articles

Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective.

Nthontho K, Ndlovu A, Sharma K, Kasvosve I, Hertz D, Paganotti G Pharmgenomics Pers Med. 2022; 15:613-652.

PMID: 35761855 PMC: 9233488. DOI: 10.2147/PGPM.S308531.

Nevirapine hair and plasma concentrations and HIV-1 viral suppression among HIV infected ante-partum and post-partum women attended in a mother and child prevention program in Maputo city, Mozambique.

Cuco R, Loquiha O, Juga A, Couto A, Meggi B, Vubil A PLoS One. 2022; 17(2):e0261522.

PMID: 35143515 PMC: 8830619. DOI: 10.1371/journal.pone.0261522.

CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations-Implication for Drug Safety, Dosing, and Individualized Therapy.

Langmia I, Just K, Yamoune S, Brockmoller J, Masimirembwa C, Stingl J Front Genet. 2021; 12:692234.

PMID: 34322158 PMC: 8313315. DOI: 10.3389/fgene.2021.692234.

Association of Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana.

Maseng M, Tawe L, Thami P, Seatla K, Moyo S, Martinelli A Pharmgenomics Pers Med. 2021; 14:335-347.

PMID: 33758532 PMC: 7981136. DOI: 10.2147/PGPM.S289471.

Effects of CYP2B6 polymorphisms on plasma nevirapine concentrations: a systematic review and meta-analysis.

Yoon H, Cho Y, Yee J, Gwak H Sci Rep. 2020; 10(1):17390.

PMID: 33060725 PMC: 7562737. DOI: 10.1038/s41598-020-74506-x.

References

Gazzard B, Anderson J, Babiker A, Boffito M, Brook G, Brough G . British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008; 9(8):563-608. DOI: 10.1111/j.1468-1293.2008.00636.x. View

Byakika-Tusiime J, Chinn L, Oyugi J, Obua C, Bangsberg D, Kroetz D . Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults. PLoS One. 2008; 3(12):e3981. PMC: 2602850. DOI: 10.1371/journal.pone.0003981. View

Schipani A, Wyen C, Mahungu T, Hendra H, Egan D, Siccardi M . Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. J Antimicrob Chemother. 2011; 66(6):1332-9. PMC: 3092713. DOI: 10.1093/jac/dkr087. View

Koal T, Burhenne H, Romling R, Svoboda M, Resch K, Kaever V . Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2005; 19(21):2995-3001. DOI: 10.1002/rcm.2158. View

Laurent C, Kouanfack C, Koulla-Shiro S, Nkoue N, Bourgeois A, Calmy A . Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet. 2004; 364(9428):29-34. DOI: 10.1016/S0140-6736(04)16586-0. View

Erickson D, Mather G, TRAGER W, Levy R, Keirns J . Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999; 27(12):1488-95. View

Veldkamp A, Weverling G, Lange J, Montaner J, Reiss P, Cooper D . High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS. 2001; 15(9):1089-95. DOI: 10.1097/00002030-200106150-00003. View

DAvolio A, Baietto L, Siccardi M, Sciandra M, Simiele M, Oddone V . An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther Drug Monit. 2008; 30(6):662-9. DOI: 10.1097/FTD.0b013e318189596d. View

Gonzalez de Requena D, Bonora S, Garazzino S, Sciandra M, DAvolio A, Raiteri R . Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting. Antimicrob Agents Chemother. 2005; 49(9):3966-9. PMC: 1195440. DOI: 10.1128/AAC.49.9.3966-3969.2005. View

10.

Almond L, Edirisinghe D, Dalton M, Bonington A, Back D, Khoo S . Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharmacol Ther. 2005; 78(2):132-42. DOI: 10.1016/j.clpt.2005.04.004. View

11.

Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee B . Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005; 15(1):1-5. DOI: 10.1097/01213011-200501000-00001. View

12.

Zukunft J, Lang T, Richter T, Hirsch-Ernst K, Nussler A, Klein K . A natural CYP2B6 TATA box polymorphism (-82T--> C) leading to enhanced transcription and relocation of the transcriptional start site. Mol Pharmacol. 2005; 67(5):1772-82. DOI: 10.1124/mol.104.008086. View

13.

Lhomme R, Muro E, Droste J, Wolters L, van Ewijk-Beneken Kolmer N, Schimana W . Therapeutic drug monitoring of nevirapine in resource-limited settings. Clin Infect Dis. 2008; 47(10):1339-44. DOI: 10.1086/592694. View

14.

Ter Heine R, Rosing H, van Gorp E, Mulder J, van der Steeg W, Beijnen J . Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 867(2):205-12. DOI: 10.1016/j.jchromb.2008.04.003. View

15.

DAvolio A, Simiele M, Siccardi M, Baietto L, Sciandra M, Bonora S . HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. J Pharm Biomed Anal. 2010; 52(5):774-80. DOI: 10.1016/j.jpba.2010.02.026. View

16.

Hosseinipour M, Corbett A, Kanyama C, Mshali I, Phakati S, Rezk N . Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults. AIDS. 2006; 21(1):59-64. DOI: 10.1097/QAD.0b013e3280117ca0. View

17.

Stohr W, Back D, Dunn D, Sabin C, Winston A, Gilson R . Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther. 2008; 13(5):675-85. View

18.

Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer N . Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother. 2008; 61(4):914-8. PMC: 3596857. DOI: 10.1093/jac/dkn029. View

19.

Kouanfack C, Laurent C, Peytavin G, Ciaffi L, Ngolle M, Nkene Y . Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon. J Acquir Immune Defic Syndr. 2008; 48(2):216-9. DOI: 10.1097/QAI.0b013e3181743955. View

20.

Chou M, Bertrand J, Segeral O, Verstuyft C, Borand L, Comets E . Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Antimicrob Agents Chemother. 2010; 54(10):4432-9. PMC: 2944557. DOI: 10.1128/AAC.00512-10. View